Anti-Angiogenic Therapy in Renal Cell Carcinoma

Authors: Sharma, Shree G.; Nanda, Sudip; Longo, Santo

Source: Recent Patents on Anti-Cancer Drug Discovery, Volume 5, Number 1, January 2010 , pp. 77-83(7)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $113.00 plus tax (Refund Policy)

Abstract:

Renal cell carcinoma (RCC) is one of the most common cancers in the United States. Recent achievements in translational research have lead to significant developments in treatment strategies for this malignancy. RCC is a richly vascular neoplasm. A better understanding of its biology has helped in the development of antiangiogenic therapy. Vascular endothelial growth factor (VEGF) is the most important molecular target in the treatment of RCC. Patents have been filed for anti-VEGF and other molecular pathways involved in the pathogenesis of RCC.

Keywords: Angiogenesis; renal cell carcinoma; VHL; VEGF; sorafenib; sumitinib; bevacizumab; temsirolimus; mTOR; angiopoietins

Document Type: Research article

DOI: http://dx.doi.org/10.2174/157489210789702181

Publication date: 2010-01-01

More about this publication?

Recent Patents on Anti-Cancer Drug Discovery publishes review articles on recent patents in the field of anti-cancer drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-cancer drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-cancer drug design and discovery.